Sign up United Kingdom
Evgen Pharma (LON:EVG)

Evgen Pharma (LON:EVG)


Share Price
18.65 p
Change
1.148 (6.56 %)
Market Cap
£18.45 m
Proactive Investors - Run By Investors For Investors

Evgen Pharma RNS Release

Directorate Changes


RNS Number : 6955G
Evgen Pharma PLC
08 November 2018
 

For immediate release

8 November 2018

 

 

Evgen Pharma plc

("Evgen" or "the Company")

 

Directorate Changes

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the appointment with immediate effect of Susan Clement-Davies, a highly experienced investment banker, as a Non-Executive Director. Simultaneously, Marc d'Abbadie, a Non-Executive Director and representative of one of the Company's early stage investors, will step down from the Board.

Susan has more than 25 years of capital markets and investment banking experience gained at banks including Bank of Tokyo (now MUFG Bank), BZW (now Barclays) and Citigroup. She worked as a managing director at Torreya Partners LLC, a global investment bank focused on life sciences, from 2014 until earlier this year. Susan's charitable work includes positions on the fund-raising committees of the Institute of Cancer Research and Great Ormond Street Hospital.

Barry Clare, Evgen's Chairman, said: "I'm delighted to welcome Susan Clement-Davies to Evgen's Board. Her extensive investment banking and life sciences experience will be of great value to the Company as we prepare for the commercialisation of our product pipeline. On behalf of the Board, I would like to extend our thanks to Marc d'Abbadie for his support and guidance both before and after Evgen's AIM flotation. We wish him well for the future."

Susan Elizabeth Clement-Davies (née Lewis) is 56 years of age. There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

Enquiries:

Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

www.evgen.com

c/o +44 (0) 20 7466 5000

 



Buchanan

Mark Court, Sophie Wills, Tilly Abraham

+44 (0) 20 7466 5000

 



Northland Capital Partners Limited

Matthew Johnson, Gerry Beaney (Corporate Finance)

Rob Rees (Corporate Broking)

 

+44 (0) 20 3861 6625

WG Partners LLP

Nigel Barnes, Claes Spång

+44 (0) 20 3705 9330

Notes for editors:

About Evgen Pharma plc

Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/ 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
BOADDLFBVFFLFBX

Evgen Pharma Timeline

Article
October 21 2015

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use